TCM
AXSM icon

Tradewinds Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Tradewinds Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-300
Closed -$11K – 780
2021
Q4 		$11K Buy
+300
New +$11K ﹤0.01% 466

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Tradewinds Capital Management's AXSM Position: Q1 2022 in Review

Tradewinds Capital Management sold out of Axsome Therapeutics (AXSM) in Q1 2022, closing a stake of 300 shares — an estimated $11K sold.

Tradewinds Capital Management first reported a position in AXSM in Q4 2021 and held it in 1 quarter. The position peaked at $11K in Q4 2021. 175 funds tracked by Wall St. Rank hold AXSM as of Q1 2022.

  • Tradewinds Capital Management reported no remaining Axsome Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Tradewinds Capital Management sold 300 Axsome Therapeutics shares in Q1 2022, an estimated $11K.
  • Tradewinds Capital Management first reported a position in Axsome Therapeutics in Q4 2021 and held it in 1 quarter.
  • Tradewinds Capital Management's Axsome Therapeutics position peaked at $11K in Q4 2021.
  • 175 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2022.

Based on Tradewinds Capital Management's 13F filing for Q1 2022, filed 25 Apr 2022.